TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00982917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stamp-in-Safety Curriculum
Description: 30 minute curriculum on playground safety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stamp-in-Safety Curriculum
Description: 30 minute curriculum on playground safety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stamp-in-Safety curriculum
Description: 30 minute lesson on playground supervision

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stamp-in-Safety curriculum
Description: 30 minute lesson on playground supervision
Study: NCT01658241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: 40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
Study: NCT05470231

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
Study: NCT02543281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive cardiac resynchronization therapy
Description: The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cardiac Resynchronization Therapy
Description: CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
Study: NCT04555577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT03509909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: Manualized hatha yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive physical activity
Description: Manualized stretching and strengthening
Study: NCT03821506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Light
Description: Dynamic Lighting system

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standard lighting system
Study: NCT04560946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Augmented Cognitive Training (PACT)
Description: Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual
Description: Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software.
Study: NCT05168085

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Providing 1 egg per day fo 6 months to infants
Study: NCT01773746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal Resuscitation
Description: CPAP or Positive Pressure Ventilation will be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal Resuscitation
Description: CPAP or Positive Pressure Ventilation will be provided.
Study: NCT01189929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane®
Description: Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
Study: NCT01532414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: oral, capsules, taken one time daily, for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: oral, capsules, taken one time daily, for 3 months
Study: NCT01189929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
Study: NCT04290533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active High Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
Study: NCT04075396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Participants will receive Lazertinib tablets once daily.
Study: NCT03079518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: single shot infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: single shot infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood withdrawal
Description: for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
Study: NCT01179750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Coagulating Shears
Description: comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
Study: NCT01532414

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule taken one time daily for 3 months
Study: NCT01278238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb compression
Description: Tight bandaging of lower extremity up to hips with compression bandages

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Neither phenylephrine nor lower limb bandaging
Study: NCT01961297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Description: Sodium oxybate
Study: NCT04343430

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography
Description: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample collection will be performed before discharge from hospital

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Telephone interview
Description: Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study: NCT01651819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urological physical therapy
Description: Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
Study: NCT00752739

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT06328270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone - oxygen Therapy
Description: Ozone gas is a structurally unstable molecule that contains three oxygen atoms.
Study: NCT03079518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood withdrawal
Description: for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
Study: NCT02848105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPA
Description: Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
Study: NCT00166244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma.
Study: NCT02388360

Intervention type: DRUG
Group type: OTHER
Intervention: topical prostaglandin analogs
Study: NCT02851693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) with Vivosight
Description: OCT used is Vivosight for diagnosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) with Skintell
Description: OCT used is Skintell for diagnosis
Study: NCT02187692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT
Description: The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
Study: NCT03352726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBV712 IHRP
Description: DBV712 Solution for Skin Prick Test
Study: NCT04142255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
Study: NCT02101138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
Study: NCT02238769

Intervention type: DEVICE
Intervention: 18F-FluoroethylCholine PET
Description: 18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
Study: NCT02278666

Intervention type: PROCEDURE
Intervention: aortic valve replacement
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve

Intervention type: PROCEDURE
Intervention: aortic valve replacement
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve

Intervention type: PROCEDURE
Intervention: aortic valve replacement
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve

Intervention type: DEVICE
Intervention: biological prosthetic valve
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve

Intervention type: DEVICE
Intervention: biological prosthetic valve
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve

Intervention type: DEVICE
Intervention: biological prosthetic valve
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve

Intervention type: DEVICE
Intervention: Mechanical valve
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve

Intervention type: DEVICE
Intervention: Mechanical valve
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve

Intervention type: DEVICE
Intervention: Mechanical valve
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve
Study: NCT02940249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple polyphenols
Description: Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple polyphenols
Description: Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple polyphenols
Description: Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01593020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
Study: NCT06328270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: 1 ml betamethasone
Study: NCT00097227

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B.
Study: NCT01593020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
Study: NCT04251442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoSensor Verasense Technology
Description: IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
Study: NCT02907905

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: capillary sampling
Description: After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.~The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results
Study: NCT03411941

Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: IVT(Intravitreal) aflibercept treatment in routine clinical practice.
Study: NCT02754596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intraocular Implant, high elution
Description: Surgical implant placed within the eye to elute travoprost.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intraocular Implant, low elution
Description: Surgical implant placed within the eye to elute travoprost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution, 0.5%
Description: Instillation of one drop of timolol in the study eye twice daily